U.S. markets closed
  • S&P Futures

    4,222.75
    +12.75 (+0.30%)
     
  • Dow Futures

    33,355.00
    +95.00 (+0.29%)
     
  • Nasdaq Futures

    13,452.00
    +60.00 (+0.45%)
     
  • Russell 2000 Futures

    1,975.50
    +6.00 (+0.30%)
     
  • Crude Oil

    91.56
    -0.37 (-0.40%)
     
  • Gold

    1,787.80
    -7.80 (-0.43%)
     
  • Silver

    20.57
    -0.17 (-0.83%)
     
  • EUR/USD

    1.0298
    -0.0004 (-0.04%)
     
  • 10-Yr Bond

    2.7860
    -0.0110 (-0.39%)
     
  • Vix

    19.74
    -2.03 (-9.32%)
     
  • GBP/USD

    1.2206
    -0.0012 (-0.10%)
     
  • USD/JPY

    132.8460
    -0.0270 (-0.02%)
     
  • BTC-USD

    24,069.45
    +1,245.68 (+5.46%)
     
  • CMC Crypto 200

    570.02
    +38.80 (+7.30%)
     
  • FTSE 100

    7,507.11
    +18.96 (+0.25%)
     
  • Nikkei 225

    27,819.33
    -180.63 (-0.65%)
     

InflaRx Shares Are Flying Higher After Emergency Use Nod Plans For Its COVID-19 Treatment

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • Earlier today, InflaRx N.V. (NASDAQ: IFRX) announced plans to apply for Emergency Use Authorization (EUA) for vilobelimab for critically ill COVID-19 patients, following encouraging interactions with the FDA at a recently held Type B meeting.

  • Vilobelimab is InflaRx’s novel intravenously administered first-in-class anti-C5a monoclonal antibody that selectively binds to free complement activation factor C5a.

  • At the FDA meeting, the company discussed in detail the previously announced data from the Phase 3 part of the PANAMO study.

  • Results showed a relative reduction in 28-day all-cause mortality of 23.9% compared to placebo (vilobelimab 31.7% vs. placebo 41.6%). In Western European countries (n=209), there was a relative reduction in 28-day all-cause mortality of 43%.

  • InflaRx received guidance from the FDA on deliverables related to its planned submission for EUA, which is expected in 3Q22.

  • HC Wainwright anticipates a launch in 2024 for vilobelimab for COVID-19 patients with sales of $14 million that year and $135 million in 2028.

  • The analyst reiterates the Buy rating with a price target of $7.

  • Price Action: IFRX shares are up 46.40% at $2.04 during the market session on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.